Crinetics Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation
Depreciation and amortization
Noncash lease expense
Accretion of purchase discounts and amortization of premiums on investment securities, net
Loss on equity method investment
Loss on disposal of property and equipment
Change in valuation of derivative asset
Other, net
Changes in operating assets and liabilities:
Trade accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable and accrued expenses, compensation and related expenses, and other non-current liabilities
Deferred revenue
Operating lease liabilities

Net cash used in operating activities
CASH FLOWS FROM Investing activities
Purchases of investment securities
Purchase of Radionetics preferred stock
Maturities and sale of investment securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
CASH FLOWS FROM Financing activities
Proceeds from exercise of stock options
Offering costs related to issuance of common stock
Proceeds from exercise of stock options and shares issued under Employee Stock Purchase Plan
Net cash provided by financing activities
Net change in cash, cash equivalents and restricted cash
Exchange rate changes on cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash - beginning of period
Cash, cash equivalents and restricted cash - end of period
Non-cash investing and financing activities
Derivative asset obtained for Investment in Radionetics common stock
Private company shares received under licensing arrangements
Exercise of Radionetics Warrant
Stock issued under Employee Stock Purchase Plan
Stock options exercised receivable
Receivable for common stock issuances
Accrued financing costs
Stock held in trust
Amounts accrued for purchases of property and equipment
Right-of-use asset obtained in exchange for lease obligations
Leasehold improvements paid by the lessor
Change in unvested stock liability

Components of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash
Restricted cash, net of current portion

Comments